Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00891033 · ClinicalTrials.gov registry record · Phase 1
Panobinostat/Velcade in Multiple Myeloma
A Phase 1 study, sponsored by University of Arkansas.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00891033 is a Phase 1 study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 12 participants.
The verdict
NCT00891033, a Phase 1 study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Multiple myeloma (MM) accounts for approximately 1% of all malignancies and 10% of hematological tumors, representing the second most frequently occurring hematological malignancy in the United States. At any one time, 50,000 people suffer from MM, and approximately 15,000 are diagnosed each year. The median age is approximately 65 years, although occasionally MM occurs in the second decade of life. Bortezomib and panobinostat intravenous (IV) are active agents in multiple myeloma and appear to work through different biochemical pathways, suggesting that there may be a synergistic effect using the combination. Both compounds have shown anabolic bone effect, which has been associated to significant anti-myeloma activity. Primary objectives: * To assess the toxicity of bortezomib combined with one of 4 doses of panobinostat IV in patients with relapsed/refractory multiple myeloma, and * To find the most appropriate doses of bortezomib and panobinostat IV in the combination. Secondary objective: * To assess the effect of bortezomib in combination with panobinostat IV on inducing osteoblast activation in patients with relapsed/refractory myeloma.
Interventions
- DRUG Panobinostat
- DRUG Bortezomib (Velcade)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-04 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00891033
The ClinicalTrials.gov registry entry for NCT00891033 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Panobinostat is the first listed.
NCT00891033 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00891033 about?
NCT00891033 is a clinical study titled "Panobinostat/Velcade in Multiple Myeloma". Multiple myeloma (MM) accounts for approximately 1% of all malignancies and 10% of hematological tumors, representing the second most frequently occurring hematological malignancy in the United States. At any one time, 50,000 people suffer from MM, and approximately 15,000 are diagnosed each year. T...
What is the current status of trial NCT00891033?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2009-04. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00891033?
The interventions under investigation include: Panobinostat (DRUG), Bortezomib (Velcade) (DRUG).
Who is sponsoring clinical trial NCT00891033?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.